Author

L. Hao

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Sep 2026

Nanotherapeutic Strategies for MASLD: From Pathological Mechanisms to Targeted Delivery Systems

Abstract Metabolic dysfunction-associated steatotic liver disease (MASLD) is a progressive metabolic liver disorder driven by hepatic lipid overload, oxidative stress, mitochondrial dysfunction, innate immune activation, insulin resistance, gut–liver axis dysregulation, and liver fibrosis. These interconnected patholog...

Na Li, Dong-Qi Zhou, Fang-Hang Ye et al. · International Journal of Nan... · 0 citations

#gene editing Open access Oct 2026

Metabolic-epigenetic regulation of the HBV cccDNA reservoir: pathways underpinning viral persistence

Chronic hepatitis B virus (HBV) infection remains a global public health burden, and functional cure represents the primary goal of clinical management. The nuclear covalently closed circular DNA (cccDNA) minichromosome stably maintained in infected hepatocytes constitutes the major barrier to HBV cure. Clinically, f...

Qing Peng, Li-Yuan Hao, Sheng-Hao Li et al. · Frontiers in Microbiology · 0 citations

Open access Sep 2026

Deciphering early molecular responses to aristolactam I associated with hepatocellular carcinoma: Computational prediction of a core gene signature and identification of transcription-translation uncoupling under acute aristolactam I exposure.

Aristolochic acid I (AAI) is a potent hepatocarcinogen mainly activated to aristolactam I (ALI). The molecular mechanisms driving ALI‑associated hepatocellular carcinoma (HCC), particularly post‑transcriptional events linking acute liver injury to malignant transformation, remain poorly defined. Here, we integrated pha...

Qing Peng, L. Hao, Sheng-Hao Li et al. · Ecotoxicology and Environmen... · 0 citations